PATENT CLAIM ANALYSIS

Application Number: 15771496
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "275000"]

Abstract:
In the invention provides a WNT/β-catenin signal transduction inhibitor selected from (i) axitinib, (ii) pazopanib, (iii) orlistat, (iv) topotecan, (v) pharmaceutically effective substitution derivatives thereof, or (vi) pharmaceutically acceptable salts, or solvates or hydrates thereof, diastereoisomers, tautomers, enantiomers, and prodrugs and active metabolites thereof, for use in the treatment or prevention of a disease or condition in which WNT/β-catenin signal transduction is a contributing factor and for use in a method for the immunotherapy of a hyperproliferative or neoplastic disease or condition in a subject in which DCs are administered to the subject. The invention further provides an in vitromethod for diagnosing WNT/β-catenin dependent cancers, said method comprising (i) contacting a sample of cells from a test cancer with one or more of the WNT/β-catenin signal transduction inhibitors disclosed herein, and (ii) assessing the effects of said inhibitor on said sample.

Claim (Index 21):
The method of  claim 1 , wherein said disease or condition is a disorder or dysfunction in the metabolism of carbohydrates by a subject.

Metadata:
- Claim Count in Document: 24.0
- Percentile: 91.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14389310', '12302317', '15204804', '11707386', '14770474']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7943903544763218
- 35 USC 102 Novelty (BERT): 0.5334512287281976
- Combined Prediction Score: 0.7682964419015094
- Mean Citation Score: 317.171546
- Max Citation Score: 350.74487
- Similarity Product: 186.32200655896665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test